Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NYSE: TAK) | Delayed: 20.24 -0.12 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.36 | 52 Week High | $0.55 | |||
| Open | $20.28 | 52 Week Low | $0.55 | |||
| Day High | $20.39 | P/E | N/A | |||
| Day Low | $20.17 | EPS | $-0.20 | |||
| Volume | 2,099,212 | |||||
